Company Announcement
Read the original post:
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Related Post
- Tauriga Sciences Inc. Showcases Blister Pack Design for its Evergreen Mint Flavor, Delta 8 THC Infused, Version of Tauri-Gum - April 18th, 2021
- Immutep Receives A$1,155,055 R&D Tax Incentive - April 18th, 2021
- New Data at AAN 2021 from Across Biogen’s MS Portfolio Demonstrate Positive Impact of Treatment on People Living with Relapsing Multiple Sclerosis - April 18th, 2021
- TG Therapeutics Announces Positive Results from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at... - April 18th, 2021
- Zogenix Presents New Data from a Study Highlighting the Impact of Treatment with FINTEPLA® (Fenfluramine) Oral Solution on Dravet Syndrome Patients,... - April 18th, 2021
- Fulgent Genetics to Announce First Quarter 2021 Financial Results on Thursday May 6, 2021 - April 18th, 2021
- Aleafia Health to Announce 2021 First Quarter Results - April 18th, 2021
- Aprea Therapeutics to Host Virtual R&D Day on April 22, 2021 - April 18th, 2021
- Vistin Pharma ASA: Invitation to Q1 2021 conference call - April 18th, 2021
- LIDDS Annual Report 2020 - April 18th, 2021
- Adverum Biotechnologies to Present New Data from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at ARVO 2021 - April 18th, 2021
- Virbac : Declaration of the number of shares and voting rights March 2021 - April 18th, 2021
- Sanofi completes Kiadis acquisition - April 18th, 2021
- Brickell Biotech Announces Presentation of US Phase 3 Open-Label Long-Term Safety Study Results for Sofpironium Bromide Gel at the Late-Breaking... - April 18th, 2021
- Cosmos Holdings Reports Revenue Growth of 40% to a Record $55.4 Million and Achieves Profitability for 2020 - April 18th, 2021
- Auxly Receives Approval to Begin Trading on the Toronto Stock Exchange April 20, 2021 - April 18th, 2021
- AnPac Bio Reports Record Q1 for Paid CDA-Based Cancer Testing Volume in 2021, Increasing Approximately 130% Compared to Q1, 2020 - April 18th, 2021
- Apellis to Showcase Leadership in Retina at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting - April 18th, 2021
- Avadel Presents New Data from its Pivotal REST-ON Phase 3 Trial of FT218, once-nightly sodium oxybate, at the 2021 American Academy of Neurology... - April 18th, 2021
- VASCEPA® (Icosapent Ethyl) Reported to Impact Vulnerable Coronary Plaque Features in New Analyses of EVAPORATE Study Presented as Late-Breaking... - April 18th, 2021
- Virbac: very strong growth in revenue in the first quarter of 2021 at +22.6% at comparable exchange rates and scope (+12.3% at constant rates), driven... - April 16th, 2021
- GBS, Inc. Receives Approval to Commence Validation Clinical Study for Rapid SARS-CoV-2 Diagnostic Test - April 16th, 2021
- TG Therapeutics to Host Investor & Analyst Event to Preview Results from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple... - April 16th, 2021
- Infant Bacterial Therapeutics receives additional patent protection in China - April 16th, 2021
- Nabriva Commences Exclusive Distribution of SIVEXTRO® (tedizolid phosphate) in the U.S. - April 16th, 2021
- GigaGen Publishes Research on Company’s Recombinant Hyperimmunes in Nature Biotechnology - April 16th, 2021
- Pacific Biosciences of California, Inc. First Quarter 2021 Financial Results Call - April 16th, 2021
- Avid Bioservices Announces Completion of Redemption of Series E Convertible Preferred Stock - April 16th, 2021
- Collegium to Host Conference Call to Discuss First Quarter 2021 Financial Results and Provide Corporate Update - April 16th, 2021
- Adamis Pharmaceuticals Announces 2020 Financial Results and Business Update - April 16th, 2021
- Biogen Grows Presence in China with the Approval of TECFIDERA® (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis - April 16th, 2021
- Praxis Precision Medicines Adds Development Expertise to Board of Directors with Appointment of Jeffrey Chodakewitz, M.D. - April 16th, 2021
- 22nd Century Stands Fully Prepared to Enable New Zealand Proposal to Advance Nationwide Smoke-Free Action Plan - April 16th, 2021
- Golden Leaf to Report Fiscal 2020 and Fourth Quarter 2020 Results on Tuesday April 27th - April 16th, 2021
- Tower One Construction Update for the Month of March 2021 - April 16th, 2021
- ContraFect Invited to Present at the Inaugural Anti-Infectives Drug Development Summit - April 16th, 2021
- Revive Reschedules Annual and Special Meeting and Provides Dial-In Information - April 16th, 2021
- Relay Therapeutics Extends Leadership in Integrating Computational and Experimental Approaches to Create Precision Medicines by Acquiring ZebiAI - April 16th, 2021
- Prostate cancer study to be initiated at Uppsala University Hospital with NanoZolid technology® - April 16th, 2021
- New data for Roche’s OCREVUS (ocrelizumab) reinforce significant benefit on slowing disease progression in relapsing and primary progressive... - April 16th, 2021
- AzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for Grade 1 Immune Checkpoint Inhibitor-Associated Colitis - April 14th, 2021
- Artelo Biosciences Reports Second Quarter Fiscal 2021 Financial Results and Provides Business Update - April 14th, 2021
- Longeveron Announces Positive Results of Phase I Clinical Study of Lomecel-B Cell Therapy for Alzheimer’s Disease - April 14th, 2021
- SEngine Precision Medicine Presents Data at 2021 AACR Annual Meeting Demonstrating Clinical Utility and Predictive Value of PARIS® Test in Ovarian... - April 14th, 2021
- Akouos Receives Orphan Drug and Rare Pediatric Disease Designations for AK-OTOF for the Treatment of Otoferlin Gene-Mediated Hearing Loss - April 14th, 2021
- Senti Bio Enters Collaboration with Spark Therapeutics to Develop Next-Generation Precision Gene Therapies - April 14th, 2021
- Passing of Genmab A/S’ Annual General Meeting - April 14th, 2021
- A civil case has been initiated in the claim of JSC Olainfarm for the damage caused - April 14th, 2021
- GeneThera’s Strategy for the Development of a Global Zoonotic Diseases Surveillance System Using Smart Testing Technology - April 14th, 2021
- Nicox: 2021 Ordinary and Extraordinary General Meetings postponed to April 28, 2021 - April 14th, 2021
- Lixte Biotechnology Holdings, Inc. Announces the Appointment of Gil N Schwartzberg to its Board of Directors - April 14th, 2021
- NKMax and Merck KGaA, Darmstadt, Germany Expand Clinical Collaboration to Include Phase I/IIa Trial Investigating the Combination of SNK01 with... - April 14th, 2021
- Tauriga Sciences Inc. to Launch Non-Fungible Tokens (NFTs) Creation & Content Division, as Part of its Long-Term Branding, Marketing, and... - April 14th, 2021
- Notice of Annual General Meeting of LIDDS AB (publ) - April 14th, 2021
- Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2020 Financial Results Conference Call and Business Update - April 14th, 2021
- PRA Health Sciences selected by Maryland State Medical Society to supply remote patient monitoring and telehealth services - April 14th, 2021
- Nurix Therapeutics Reports First Quarter Fiscal 2021 Financial Results and Provides a Corporate Update - April 14th, 2021
- BIOPHYTIS Identifies False Report Regarding COVA study - April 14th, 2021
- Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees and a New Member of Management in... - April 14th, 2021
- ProQR Announces Publication in Nature Medicine for Sepofarsen in Leber Congenital Amaurosis 10 - April 14th, 2021
- Black Diamond Therapeutics Announces Preclinical Data Presentations on BDTX-189 and BDTX-1535 at American Association for Cancer Research Annual... - April 10th, 2021
- Gennao Bio Presents New Data on Novel Gene Monoclonal Antibody Platform Technology at the American Association for Cancer Research (AACR) 2021 Annual... - April 10th, 2021
- MacroGenics Announces Presentations at the 2021 AACR Annual Meeting - April 10th, 2021
- Kronos Bio Presents Preclinical Data for Oral CDK9 Inhibitor KB-0742 Demonstrating Sustained Inhibition of Tumor Growth in Multiple Cancers at AACR... - April 10th, 2021
- Allogene Therapeutics Presents Preclinical Research Highlighting a Novel TurboCAR™ T Cell Technology Designed to Overcome Immune Suppression in... - April 10th, 2021
- NextCure Presents Preclinical Data for NC762 at American Association for Cancer Research (AACR) Annual Meeting 2021 - April 10th, 2021
- Achilles Therapeutics Demonstrates cNeT Product Characterization and Post-Infusion Tracking in a Patient Case Study at the American Association for... - April 10th, 2021
- Harpoon Therapeutics Announces Data from Poster Presentations at the AACR Annual Meeting 2021 - April 10th, 2021
- iTeos Therapeutics Announces New Preliminary Data Indicating Clinical Activity with its Anti-TIGIT Antibody, EOS-448, at the AACR Annual Meeting 2021 - April 10th, 2021
- CRISPR Therapeutics Presents Preclinical Data at AACR 2021 Supporting CD70 Knockout as a Novel Approach to Increasing CAR-T Cell Function - April 10th, 2021
- Inivata Presents New Data in Support of its Liquid Biopsy Technologies at AACR Virtual Annual Meeting 2021 - April 10th, 2021
- Codiak Presents Data at AACR 2021 Demonstrating Potential of Engineered Exosomes to Enhance the Therapeutic Index of Well-Validated Cancer... - April 10th, 2021
- Genocea to Present Novel Preclinical Inhibigen™ Data at AACR Annual Meeting 2021 - April 10th, 2021
- OncXerna Therapeutics Provides New Results from its Xerna™ RNA-based Biomarker Platform at the AACR Annual Meeting - April 10th, 2021
- HOOKIPA announces positive preliminary Phase 1 immunogenicity data for its immunotherapy candidates to treat advanced HPV16+ cancers - April 10th, 2021
- Vincerx Pharma Presents Preclinical Data on VIP236, its Lead Small Molecule Drug Conjugate, at the American Association for Cancer Research Annual... - April 10th, 2021
- Jounce Therapeutics Presents Preclinical Data from JTX-8064/LILRB2 Program at the 2021 American Association for Cancer Research (AACR) Virtual Annual... - April 10th, 2021
- Advaxis Presents Translational Biomarker Data from Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial at the American Associated for Cancer Research (AACR)... - April 10th, 2021
- TCR² Highlights Gavo-cel Translational Data and Emerging Solid Tumor Pipeline Preclinical Data at AACR Annual Meeting - April 10th, 2021
- Arch Oncology Presents New Preclinical T-ALL Data on Highly-differentiated Anti-CD47 Antibody AO-176 at AACR 2021 - April 10th, 2021
Recent Comments